Mayo Clinic Laboratories > Genetics > Pharmacogenomics > Medication-targeted testing

Medication-targeted testing 

Guide therapy selection

For specific medications with well-established pharmacogenomic associations, targeted gene testing can identify variations that impact treatment response. Our single- and multi-gene medication-targeted assays can help guide therapy choices, enabling treatment optimization for specific drugs with well-established pharmacogenomic associations.

Medication-targeted testing Test menu

Targeted panels

Certain medications, among them mood stabilizers, blood thinners, and thiopurines, are more likely to result in toxicity or have a potential for lack of efficacy in individuals with genetic variants related to metabolism or the immune system. Our medication-targeted panels can reveal genetic variants that can impact a patient’s ability to metabolize a particular drug.

Key testing


Single gene testing

Analysis of a single gene can help guide therapy when assessing a single medication.

Arylamine N-acetyltransferase type 2 (NAT2)

Catechol-O-Methyltransferase (COMT)

Dihydropyrimidine Dehydrogenase (DPYD)

Glucose-6-Phosphate Dehydrogenase (G6PD)

Human leukocyte antigen (HLA)

Interleukin 28B (IL28B)

Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

UDP-Glucuronosyltransferase 1A1 (UGT1A1)

  1. Moyer AM. NUDT15: A bench to bedside success story. Clin Biochem. 2021 Jun;92:1-8. doi:10.1016/j.clinbiochem.2021.02.007. Epub 2021 Mar 4. PMID: 33675810

Fill out the form below and one of our specialists will be in touch.